Daniel Spratt, MD, outlines the validation standards urologists should expect before adopting AI-based tools, where AI-driven digital pathology is headed, and his key takeaway from the benchmarking data.
Daniel Spratt, MD, explains how he layers MMAI results onto NCCN risk groups and how he manages discordant results in both directions.
Daniel Spratt, MD, reviews how closely MMAI-predicted 10-year distant metastasis and prostate cancer–specific mortality tracked observed STAR-CAP outcomes, including among patients treated with surgery.
Daniel Spratt, MD, explains what the STAR-CAP cohort is, what an MMAI risk estimate represents, and why calibration benchmarking differs from clinical validation.
Daniel Spratt, MD, outlines the limitations of PSA-, T stage-, and Gleason-based risk stratification and explains how AI-derived, continuous risk estimates could address them.
Daniel Spratt, MD, discusses how the ArteraAI Prostate Test (Post-RP) could help guide treatment intensification decisions.
"If your practice does not closely monitor patients and send them for early salvage radiotherapy when their PSA is 0.1 or 0.2 ng/mL, it is likely that adjuvant radiotherapy is superior," Daniel E. Spratt, MD, writes.
Published: October 2nd 2026 | Updated: October 2nd 2026
